Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Acalabrutinib + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Acalabrutinib||Calquence||ACP-196||BTK inhibitor 25||Calquence (acalabrutinib) selectively inhibits BTK, resulting in decreased B-cell receptor signaling, and potentially leading to decreased tumor cell proliferation (PMID: 27903679, PMID: 26957112). Calquence (acalabrutinib) is FDA approved for use in patients with mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma (FDA.gov).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04462328||Phase I||Acalabrutinib + Durvalumab||Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma||Not yet recruiting||USA||0|